Day: July 6, 2025

Webcast to be held Monday, July 7th at 8:00 a.m. ET SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast DetailsApogee Therapeutics’ live webcast of the Phase 2 APEX Part A results will begin...

The Board of Kvika banki hf. has approved the request from the Board of Arion banki hf. to initiate formal merger discussions between Kvika banki hf. and Arion banki hf. A letter of intent to that effect has been signed by both parties. In the ongoing merger discussions between the companies, it is proposed that the price per share in Kvika bank will be set at ISK 19.17 and ISK 174.5 per share for Arion bank in the anticipated merger. As such, shareholders of Kvika will receive 485,237,822 new shares in the merged entity, reflecting 26% ownership. A reasonable adjustment of the exchange ratio is expected in the event of a distribution made by the companies to their shareholders prior to the effective date of the merger.   The negotiations are expected to take place over the coming weeks, and further updates will be provided as appropriate...

Consolidated harvest volumes in Q2 2025 are:Farming Central Norway: 33.9Farming Northern Norway: 20.6SalMar Ocean: 6.0Icelandic Salmon: 4.0Total: 64.5All figures in 1,000 tonnes gutted weight.  The Q2 2025 report will be released on Thursday 21 August at 06:30 CEST, the following presentation will be available through Norwegian webcast at 08:00 CEST and English webcast (recording) at 10:00 CEST. Please note that the presentation will be held in Oslo and not in Trondheim as previously announced. For more information, please contact:Håkon Husby Head of Investor RelationsTel: +47 936 30 449 Email: hakon.husby@salmar.no This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act